Possible involvement of angiogenesis in chronic liver diseases: Interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress

Current Medicinal Chemistry

Volumn 19, Issue 12, 2012, Pages 1889-1898

  Kaji, K ^a   Yoshiji, H ^a   Ikenaka, Y ^a   Noguchi, R ^a   Aihara, Y ^a   Shirai, Y ^a   Douhara, A ^a   Fukui, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiogenesis; Angiotensin II; Hepatic stellate cell; Hepatocellular carcinoma; Insulin resistance; Iron chelator; Liver fibrosis; Nonalcoholic steatohepatitis; Reactive oxygen species; Vascular endothelial growth factor

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BEVACIZUMAB; BRIVANIB; DEFERASIROX; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FLUOROURACIL; IMATINIB; INTERFERON; METFORMIN; ORANTINIB; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOMATOMEDIN C; SORAFENIB; SPIRONOLACTONE; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VITAMIN K GROUP;

ANGIOGENESIS; ARTICLE; CHRONIC LIVER DISEASE; DISEASE COURSE; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; HUMANS; INSULIN RESISTANCE; LIVER; LIVER DISEASES; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84860524310     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800099848     Document Type: Article

References (169)

1. Albanis, E.; Friedman, S. L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin. Liver Dis., 2001, 5, 315-334, v-vi (Pubitemid 32472561)
2. Friedman, S. L. Liver fibrosis - from bench to bedside. J. Hepatol., 2003, 38 Suppl 1, S38-53
3. De Leve, L. D. Hepatic microvasculature in liver injury. Semin. Liver Dis., 2007, 27, 390-400 (Pubitemid 350071839)
4. Vanhaecke, T.; Foriers, A.; Geerts, A.; Shephard, E. A.; Vercruysse, A.; Rogiers, V. Pyruvate-induced long-term maintenance of glutathione stransferase in rat hepatocyte cultures. Altern. Lab. Anim., 2001, 29, 335-346 (Pubitemid 32577567)
5. Geerts, A. M.; De Vriese, A. S.; Vanheule, E.; Van Vlierberghe, H.; Mortier, S.; Cheung, K. J.; Demetter, P.; Lameire, N.; De Vos, M.; Colle, I. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int., 2006, 26, 889-898 (Pubitemid 44165258)
6. Van Steenkiste, C.; Geerts, A.; Vanheule, E.; Van Vlierberghe, H.; De Vos, F.; Olievier, K.; Casteleyn, C.; Laukens, D.; De Vos, M.; Stassen, J. M.; Carmeliet, P.; Colle, I. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology, 2009, 137, 2112-2124 e1-6
7. Befeler, A. S.; Di Bisceglie, A. M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 2002, 122, 1609-1619 (Pubitemid 34533556)
8. Okita, K.; Sakaida, I.; Hino, K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology, 2002, 62 Suppl 1, 24-28 (Pubitemid 34702016)
9. Llovet, J. M.; Bruix, J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol., 2008, 48 Suppl 1, S20-37
10. Minguez, B.; Tovar, V.; Chiang, D.; Villanueva, A.; Llovet, J. M. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol., 2009, 25, 186-194
11. Fernandez, M.; Semela, D.; Bruix, J.; Colle, I.; Pinzani, M.; Bosch, J. Angiogenesis in liver disease. J. Hepatol., 2009, 50, 604-620
12. Zhu, A. X.; Duda, D. G.; Sahani, D. V.; Jain, R. K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol., 2011, 8, 292-301
13. Brandvold, K. A.; Neiman, P.; Ruddell, A. Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene, 2000, 19, 2780-2785 (Pubitemid 30339228)
14. Li, C. Y.; Shan, S.; Huang, Q.; Braun, R. D.; Lanzen, J.; Hu, K.; Lin, P.; Dewhirst, M. W. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J. Natl. Cancer Inst., 2000, 92, 143-147 (Pubitemid 30089871)
15. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358, 2039-2049 (Pubitemid 351656458)
16. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359, 378-390
17. Azad, N. S.; Aragon-Ching, J. B.; Dahut, W. L.; Gutierrez, M.; Figg, W. D.; Jain, L.; Steinberg, S. M.; Turner, M. L.; Kohn, E. C.; Kong, H. H. Handfoot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin. Cancer Res., 2009, 15, 1411-1416
18. Verheul, H. M.; Pinedo, H. M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer, 2007, 7, 475-485 (Pubitemid 46809172)
19. Miura, S.; Saku, K. Regulation of angiogenesis and angiogenic factors by cardiovascular medications. Curr. Pharm. Des., 2007, 13, 2113-2117 (Pubitemid 47040492)
20. Heffelfinger, S. C. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des., 2007, 13, 1215-1229 (Pubitemid 46739330)
21. Maulik, N.; Das, D. K. Redox signaling in vascular angiogenesis. Free Radic. Biol. Med., 2002, 33, 1047-1060
22. Rask-Madsen, C.; King, G. L. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab., 2007, 3, 46-56 (Pubitemid 46006612)
23. Singleton, J. R.; Smith, A. G.; Russell, J. W.; Feldman, E. L. Microvascular complications of impaired glucose tolerance. Diabetes, 2003, 52, 2867-2873 (Pubitemid 37466854)
24. Tertil, M.; Jozkowicz, A.; Dulak, J. Oxidative stress in tumor angiogenesistherapeutic targets. Curr. Pharm. Des., 2010, 16, 3877-3894
25. Ushio-Fukai, M.; Alexander, R. W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD (P) H oxidase. Mol. Cell Biochem., 2004, 264, 85-97 (Pubitemid 39366107)
26. de Kloet, A. D.; Krause, E. G.; Woods, S. C. The renin angiotensin system and the metabolic syndrome. Physiol. Behav., 2010, 100, 525-534.
27. Loh, K.; Deng, H.; Fukushima, A.; Cai, X.; Boivin, B.; Galic, S.; Bruce, C.; Shields, B. J.; Skiba, B.; Ooms, L. M.; Stepto, N.; Wu, B.; Mitchell, C. A.; Tonks, N. K.; Watt, M. J.; Febbraio, M. A.; Crack, P. J.; Andrikopoulos, S.; Tiganis, T. Reactive oxygen species enhance insulin sensitivity. Cell Metab., 2009, 10, 260-272
28. Manrique, C.; Lastra, G.; Gardner, M.; Sowers, J. R. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med. Clin. North Am., 2009, 93, 569-582
29. Rains, J. L.; Jain, S. K. Oxidative stress, insulin signaling, and diabetes. Free Radic. Biol. Med., 2011, 50, 567-575
30. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature, 2005, 438, 932-936 (Pubitemid 43093958)
31. Coulon, S.; Heindryckx, F.; Geerts, A.; Van Steenkiste, C.; Colle, I.; Van Vlierberghe, H. Angiogenesis in chronic liver disease and its complications. Liver Int., 2011, 31, 146-162
32. Kalluri, R.; Sukhatme, V. P. Fibrosis and angiogenesis. Curr. Opin. Nephrol. Hypertens., 2000, 9, 413-418 (Pubitemid 30451697)
33. Medina, J.; Caveda, L.; Sanz-Cameno, P.; Arroyo, A. G.; Martin-Vilchez, S.; Majano, P. L.; Garcia-Buey, L.; Sanchez-Madrid, F.; Moreno-Otero, R. Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J. Hepatol., 2003, 38, 660-667 (Pubitemid 36560652)
34. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut, 2003, 52, 1347-1354 (Pubitemid 37026470)
35. Onori, P.; Morini, S.; Franchitto, A.; Sferra, R.; Alvaro, D.; Gaudio, E. Hepatic microvascular features in experimental cirrhosis: a structural and morphometrical study in CCl4-treated rats. J. Hepatol., 2000, 33, 555-563
36. Shibuya, M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct., 2001, 26, 25-35 (Pubitemid 32421949)
37. Karkkainen, M. J.; Petrova, T. V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene, 2000, 19, 5598-5605
38. Corpechot, C.; Barbu, V.; Wendum, D.; Kinnman, N.; Rey, C.; Poupon, R.; Housset, C.; Rosmorduc, O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology, 2002, 35, 1010-1021 (Pubitemid 34453998)
39. Salcedo, X.; Medina, J.; Sanz-Cameno, P.; Garcia-Buey, L.; Martin-Vilchez, S.; Borque, M. J.; Lopez-Cabrera, M.; Moreno-Otero, R. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology, 2005, 42, 696-701 (Pubitemid 41233664)
40. Nakamura, K.; Zen, Y.; Sato, Y.; Kozaka, K.; Matsui, O.; Harada, K.; Nakanuma, Y. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum. Pathol., 2007, 38, 1532-1546 (Pubitemid 47418965)
41. Ankoma-Sey, V.; Wang, Y.; Dai, Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology, 2000, 31, 141-148 (Pubitemid 30033700)
42. Zhao, Y.; Wang, Y.; Wang, Q.; Liu, Z.; Liu, Q.; Deng, X. Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44/42 mitogen-activated protein kinase/cyclooxygenase-2 pathway. Mol. Cell Biochem., 2012, 359, 217-223.
43. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology., 2005, 69 Suppl 3, 4-10 (Pubitemid 41680947)
44. Miura, H.; Miyazaki, T.; Kuroda, M.; Oka, T.; Machinami, R.; Kodama, T.; Shibuya, M.; Makuuchi, M.; Yazaki, Y.; Ohnishi, S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol., 1997, 27, 854-861 (Pubitemid 27454829)
45. Yamaguchi, R.; Yano, H.; Iemura, A.; Ogasawara, S.; Haramaki, M.; Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology., 1998, 28, 68-77 (Pubitemid 28299987)
46. Yamaguchi, R.; Yano, H.; Nakashima, Y.; Ogasawara, S.; Higaki, K.; Akiba, J.; Hicklin, D. J.; Kojiro, M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol. Rep., 2000, 7, 725-729
47. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Masaki, T.; Fukui, H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology, 2004, 39, 1517-1524 (Pubitemid 38702652)
48. Willis, L. M.; El-Remessy, A. B.; Somanath, P. R.; Deremer, D. L.; Fagan, S. C. Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin. Sci. (Lond), 2011, 120, 307-319
49. Abid, M. R.; Spokes, K. C.; Shih, S. C.; Aird, W. C. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J. Biol. Chem., 2007, 282, 35373-35385 (Pubitemid 350232487)
50. Wang, Y.; Zang, Q. S.; Liu, Z.; Wu, Q.; Maass, D.; Dulan, G.; Shaul, P. W.; Melito, L.; Frantz, D. E.; Kilgore, J. A.; Williams, N. S.; Terada, L. S.; Nwariaku, F. E. Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species. Am. J. Physiol. Cell Physiol., 2011, 301, C695-704
51. Ardaillou, R. Angiotensin II receptors. J. Am. Soc. Nephrol., 1999, 10 Suppl 11, S30-39 (Pubitemid 29038162)
52. Smith, G. R.; Missailidis, S. Cancer, inflammation and the AT1 and AT2 receptors. J. Inflamm. (Lond), 2004, 1, 3
53. Helmy, A.; Jalan, R.; Newby, D. E.; Hayes, P. C.; Webb, D. J. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology, 2000, 118, 565-572 (Pubitemid 30140855)
54. Munshi, M. K.; Uddin, M. N.; Glaser, S. S. The role of the renin-angiotensin system in liver fibrosis. Exp. Biol. Med. (Maywood), 2011, 236, 557-566
55. Beyazit, Y.; Ibis, M.; Purnak, T.; Turhan, T.; Kekilli, M.; Kurt, M.; Sayilir, A.; Onal, I. K.; Turhan, N.; Tas, A.; Koklu, S.; Haznedaroglu, I. C. Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis. Dig. Dis. Sci., 2011, 56, 2160-2165
56. Lugo-Baruqui, A.; Munoz-Valle, J. F.; Arevalo-Gallegos, S.; Armendariz-Borunda, J. Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. Hepatol. Res., 2010, 40, 95-104
57. Bataller, R.; Gines, P.; Nicolas, J. M.; Gorbig, M. N.; Garcia-Ramallo, E.; Gasull, X.; Bosch, J.; Arroyo, V.; Rodes, J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology, 2000, 118, 1149-1156 (Pubitemid 30346992)
58. Yoshiji, H. Anti-fibrotic therapy: Are matrix metalloproteinases friends or foes? Hepatol. Res., 2009, 39, 748-750
59. Iredale, J. P. Tissue inhibitors of metalloproteinases in liver fibrosis. Int. J. Biochem. Cell Biol., 1997, 29, 43-54 (Pubitemid 27096418)
60. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Yanase, K.; Namisaki, T.; Imazu, H.; Fukui, H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology, 2002, 36, 850-860
61. Murawaki, Y.; Ikuta, Y.; Idobe, Y.; Kitamura, Y.; Kawasaki, H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J. Hepatol., 1997, 26, 1213-1219 (Pubitemid 27346632)
62. Yoshiji, H.; Kuriyama, S.; Fukui, H. Blockade of renin-angiotensin system in antifibrotic therapy. J. Gastroenterol. Hepatol., 2007, 22 Suppl 1, S93-95 (Pubitemid 46849000)
63. Hirose, A.; Ono, M.; Saibara, T.; Nozaki, Y.; Masuda, K.; Yoshioka, A.; Takahashi, M.; Akisawa, N.; Iwasaki, S.; Oben, J. A.; Onishi, S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 2007, 45, 1375-1381 (Pubitemid 46918321)
64. Jonsson, J. R.; Clouston, A. D.; Ando, Y.; Kelemen, L. I.; Horn, M. J.; Adamson, M. D.; Purdie, D. M.; Powell, E. E. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology, 2001, 121, 148-155 (Pubitemid 32591525)
65. Ohishi, T.; Saito, H.; Tsusaka, K.; Toda, K.; Inagaki, H.; Hamada, Y.; Kumagai, N.; Atsukawa, K.; Ishii, H. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Res. 2001, 21, 147-158 (Pubitemid 32899085)
66. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001, 34, 745-750 (Pubitemid 32927999)
67. Fort, J.; Pilette, C.; Veal, N.; Oberti, F.; Gallois, Y.; Douay, O.; Rosenbaum, J.; Cales, P. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J. Hepatol., 1998, 29, 263-270 (Pubitemid 28352812)
68. Okanoue, T.; Itoh, Y.; Minami, M.; Sakamoto, S.; Yasui, K.; Sakamoto, M.; Nishioji, K.; Murakami, Y.; Kashima, K. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J. Hepatol., 1999, 30, 653-659 (Pubitemid 29151907)
69. Yoshiji, H.; Noguchi, R.; Kuriyama, S.; Ikenaka, Y.; Yoshii, J.; Yanase, K.; Namisaki, T.; Kitade, M.; Masaki, T.; Fukui, H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288, G907-913 (Pubitemid 40563130)
70. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Fukui, H. Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. Liver Int., 2005, 25, 153-161 (Pubitemid 40298258)
71. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Ikenaka, Y.; Yoshii, J.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Asada, K.; Akahane, T.; Tsujimoto, T.; Uemura, M.; Fukui, H. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int. J. Mol. Med., 2006, 17, 899-904
72. Corey, K. E.; Shah, N.; Misdraji, J.; Abu Dayyeh, B. K.; Zheng, H.; Bhan, A. K.; Chung, R. T. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int., 2009, 29, 748-753
73. Terui, Y.; Saito, T.; Watanabe, H.; Togashi, H.; Kawata, S.; Kamada, Y.; Sakuta, S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology, 2002, 36, 1022
74. Yokohama, S.; Yoneda, M.; Haneda, M.; Okamoto, S.; Okada, M.; Aso, K.; Hasegawa, T.; Tokusashi, Y.; Miyokawa, N.; Nakamura, K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology, 2004, 40, 1222-1225 (Pubitemid 39425579)
75. Lever, A. F.; Hole, D. J.; Gillis, C. R.; McCallum, I. R.; McInnes, G. T.; MacKinnon, P. L.; Meredith, P. A.; Murray, L. S.; Reid, J. L.; Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet, 1998, 352, 179-184 (Pubitemid 28327802)
76. Christian, J. B.; Lapane, K. L.; Hume, A. L.; Eaton, C. B.; Weinstock, M. A. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J. Natl. Cancer Inst., 2008, 100, 1223-1232
77. Wilop, S.; von Hobe, S.; Crysandt, M.; Esser, A.; Osieka, R.; Jost, E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol., 2009, 135, 1429-1435
78. Uemura, H.; Hasumi, H.; Kawahara, T.; Sugiura, S.; Miyoshi, Y.; Nakaigawa, N.; Teranishi, J.; Noguchi, K.; Ishiguro, H.; Kubota, Y. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int. J. Clin. Oncol., 2005, 10, 405-410 (Pubitemid 41821524)
79. Nakai, Y.; Isayama, H.; Ijichi, H.; Sasaki, T.; Sasahira, N.; Hirano, K.; Kogure, H.; Kawakubo, K.; Yagioka, H.; Yashima, Y.; Mizuno, S.; Yamamoto, K.; Arizumi, T.; Togawa, O.; Matsubara, S.; Tsujino, T.; Tateishi, K.; Tada, M.; Omata, M.; Koike, K. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer, 103, 1644-1648
80. Yoshiji, H.; Kuriyama, S.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res., 2001, 7, 1073-1078 (Pubitemid 32708747)
81. Greene, A. S.; Amaral, S. L. Microvascular angiogenesis and the reninangiotensin system. Curr. Hypertens. Rep., 2002, 4, 56-62
82. Huang, W.; Wu, Y. L.; Zhong, J.; Jiang, F. X.; Tian, X. L.; Yu, L. F. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig. Dis. Sci., 2008, 53, 1206-1210 (Pubitemid 351514639)
83. Kosaka, T.; Miyajima, A.; Takayama, E.; Kikuchi, E.; Nakashima, J.; Ohigashi, T.; Asano, T.; Sakamoto, M.; Okita, H.; Murai, M.; Hayakawa, M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate, 2007, 67, 41-49 (Pubitemid 46013466)
84. Noguchi, R.; Yoshiji, H.; Ikenaka, Y.; Namisaki, T.; Kitade, M.; Kaji, K.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via antiangiogenic activities. Oncol. Rep., 2009, 22, 355-360
85. Kerbel, R. S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol., 2001, 19, 45S-51S (Pubitemid 32880079)
86. Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol., 2002, 20, 3906-3927
87. Noguchi, R.; Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Mitoro, A.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res., 2003, 9, 6038-6045 (Pubitemid 38018091)
88. Yanase, K.; Yoshiji, H.; Ikenaka, Y.; Noguchi, R.; Kitade, M.; Kaji, K.; Yoshii, J.; Namisaki, T.; Yamazaki, M.; Asada, K.; Tsujimoto, T.; Akahane, T.; Uemura, M.; Fukui, H. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol. Rep., 2007, 17, 441-446
89. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3, 401-410 (Pubitemid 37328844)
90. Staton, C. A.; Chetwood, A. S.; Cameron, I. C.; Cross, S. S.; Brown, N. J.; Reed, M. W. The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut, 2007, 56, 1426-1432 (Pubitemid 47517839)
91. Yoshiji, H.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Tsujinoue, H.; Imazu, H.; Fukui, H. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol., 2002, 20, 1227-1231
92. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Masaki, T.; Fukui, H. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J. Hepatol., 2005, 42, 687-693
93. Yoshiji, H.; Noguchi, R.; Toyohara, M.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Yamazaki, M.; Yamao, J.; Mitoro, A.; Sawai, M.; Yoshida, M.; Fujimoto, M.; Tsujimoto, T.; Kawaratani, H.; Uemura, M.; Fukui, H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J. Hepatol., 2009, 51, 315-321
94. Yoshiji, H.; Noguchi, R.; Yamazaki, M.; Ikenaka, Y.; Sawai, M.; Ishikawa, M.; Kawaratani, H.; Mashitani, T.; Kitade, M.; Kaji, K.; Uemura, M.; Yamao, J.; Fujimoto, M.; Mitoro, A.; Toyohara, M.; Yoshida, M.; Fukui, H. Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J. Gastroenterol., 2007, 13, 3259-3261 (Pubitemid 47064593)
95. Williams, G. H. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail. Rev., 2005, 10, 7-13 (Pubitemid 40895311)
96. Funder, J. W. Minireview: Aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology, 151, 5098-5102
97. Wilkinson-Berka, J. L.; Tan, G.; Jaworski, K.; Miller, A. G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res., 2009, 104, 124-133
98. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Shirai, Y.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol. Res., 40, 540-549
99. Noguchi, R.; Yoshiji, H.; Ikenaka, Y.; Kaji, K.; Shirai, Y.; Aihara, Y.; Yamazaki, M.; Namisaki, T.; Kitade, M.; Yoshii, J.; Yanase, K.; Kawaratani, H.; Tsujimoto, T.; Fukui, H. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int. J. Mol. Med., 26, 407-413
100. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Moriya, K.; Tsujimoto, T.; Kawaratani, H.; Akahane, T.; Uemura, M.; Fukui, H. Impact of insulin resistance on the progression of chronic liver diseases. Int. J. Mol. Med., 2008, 22, 801-808
101. Kitade, M.; Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Kaji, K.; Shirai, Y.; Yamazaki, M.; Uemura, M.; Yamao, J.; Fujimoto, M.; Mitoro, A.; Toyohara, M.; Sawai, M.; Yoshida, M.; Morioka, C.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J. Gastroenterol., 2009, 15, 5193-5199
102. Hickman, I. J.; Macdonald, G. A. Impact of diabetes on the severity of liver disease. Am. J. Med., 2007, 120, 829-834 (Pubitemid 47451297)
103. Nielsen, M. F.; Caumo, A.; Aagaard, N. K.; Chandramouli, V.; Schumann, W. C.; Landau, B. R.; Schmitz, O.; Vilstrup, H. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288, G1135-1143 (Pubitemid 40741065)
104. Kawaguchi, T.; Yoshida, T.; Harada, M.; Hisamoto, T.; Nagao, Y.; Ide, T.; Taniguchi, E.; Kumemura, H.; Hanada, S.; Maeyama, M.; Baba, S.; Koga, H.; Kumashiro, R.; Ueno, T.; Ogata, H.; Yoshimura, A.; Sata, M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through upregulation of suppressor of cytokine signaling 3. Am. J. Pathol., 2004, 165, 1499-1508 (Pubitemid 39435150)
105. Hui, J. M.; Sud, A.; Farrell, G. C.; Bandara, P.; Byth, K.; Kench, J. G.; McCaughan, G. W.; George, J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology, 2003, 125, 1695-1704 (Pubitemid 37500434)
106. Petit, J. M.; Bour, J. B.; Galland-Jos, C.; Minello, A.; Verges, B.; Guiguet, M.; Brun, J. M.; Hillon, P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J. Hepatol., 2001, 35, 279-283 (Pubitemid 32803485)
107. Shintani, Y.; Fujie, H.; Miyoshi, H.; Tsutsumi, T.; Tsukamoto, K.; Kimura, S.; Moriya, K.; Koike, K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology, 2004, 126, 840-848 (Pubitemid 38298332)
108. Dai, C. Y.; Huang, J. F.; Hsieh, M. Y.; Hou, N. J.; Lin, Z. Y.; Chen, S. C.; Wang, L. Y.; Chang, W. Y.; Chuang, W. L.; Yu, M. L. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol., 2009, 50, 712-718
109. Grasso, A.; Malfatti, F.; De Leo, P.; Martines, H.; Fabris, P.; Toscanini, F.; Anselmo, M.; Menardo, G. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J. Hepatol., 2009, 51, 984-990
110. Bugianesi, E.; McCullough, A. J.; Marchesini, G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42, 987-1000 (Pubitemid 43112663)
111. Cusi, K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 2009, 13, 545-563
112. Sanyal, A. J.; Campbell-Sargent, C.; Mirshahi, F.; Rizzo, W. B.; Contos, M. J.; Sterling, R. K.; Luketic, V. A.; Shiffman, M. L.; Clore, J. N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-1192 (Pubitemid 32246672)
113. Ota, T.; Takamura, T.; Kurita, S.; Matsuzawa, N.; Kita, Y.; Uno, M.; Akahori, H.; Misu, H.; Sakurai, M.; Zen, Y.; Nakanuma, Y.; Kaneko, S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology, 2007, 132, 282-293 (Pubitemid 46108737)
114. Davila, J. A.; Morgan, R. O.; Shaib, Y.; McGlynn, K. A.; El-Serag, H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut, 2005, 54, 533-539 (Pubitemid 40403031)
115. El-Serag, H. B.; Tran, T.; Everhart, J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology, 2004, 126, 460-468 (Pubitemid 38182303)
116. El-Serag, H. B.; Richardson, P. A.; Everhart, J. E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am. J. Gastroenterol., 2001, 96, 2462-2467 (Pubitemid 32769212)
117. Sugimoto, R.; Enjoji, M.; Kohjima, M.; Tsuruta, S.; Fukushima, M.; Iwao, M.; Sonta, T.; Kotoh, K.; Inoguchi, T.; Nakamuta, M., High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int., 2005, 25, 1018-1026 (Pubitemid 41404025)
118. Svegliati-Baroni, G.; Ridolfi, F.; Di Sario, A.; Casini, A.; Marucci, L.; Gaggiotti, G.; Orlandoni, P.; Macarri, G.; Perego, L.; Benedetti, A.; Folli, F., Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology, 1999, 29, 1743-1751 (Pubitemid 29247048)
119. Siddique, A.; Kowdley, K. V. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin. Liver Dis., 2011, 15, 281-296, vii-x
120. Alexia, C.; Fallot, G.; Lasfer, M.; Schweizer-Groyer, G.; Groyer, A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol., 2004, 68, 1003-1015 (Pubitemid 39094263)
121. Natarajan, R.; Bai, W.; Lanting, L.; Gonzales, N.; Nadler, J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am. J. Physiol., 1997, 273, H2224-2231
122. Donadon, V.; Balbi, M.; Mas, M. D.; Casarin, P.; Zanette, G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int., 2010, 30, 750-758
123. Khattab, M.; Emad, M.; Abdelaleem, A.; Eslam, M.; Atef, R.; Shaker, Y.; Hamdy, L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int., 2010, 30, 447-454
124. El-Serag, H. B.; Johnson, M. L.; Hachem, C.; Morgana, R. O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology, 2009, 136, 1601-1608
125. Marchesini, G.; Bianchi, G.; Merli, M.; Amodio, P.; Panella, C.; Loguercio, C.; Rossi Fanelli, F.; Abbiati, R. Nutritional supplementation with branchedchain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology, 2003, 124, 1792-1801 (Pubitemid 36666776)
126. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; Kumada, H. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol., 2005, 3, 705-713 (Pubitemid 40984733)
127. Nishitani, S.; Takehana, K.; Fujitani, S.; Sonaka, I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288, G1292-1300 (Pubitemid 40741084)
128. Yoshiji, H.; Noguchi, R.; Kaji, K.; Ikenaka, Y.; Shirai, Y.; Namisaki, T.; Kitade, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Attenuation of insulinresistancebased hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J. Gastroenterol., 2010, 45, 443-450
129. Yoshiji, H.; Noguchi, R.; Kitade, M.; Kaji, K.; Ikenaka, Y.; Namisaki, T.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Akahane, T.; Kawaratani, H.; Uemura, M.; Fukui, H. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J. Gastroenterol., 2009, 44, 483-491
130. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; Kumada, H.; Ohashi, Y. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res., 2006, 35, 204-214
131. Jayasooriya, A. P.; Mathai, M. L.; Walker, L. L.; Begg, D. P.; Denton, D. A.; Cameron-Smith, D.; Egan, G. F.; McKinley, M. J.; Rodger, P. D.; Sinclair, A. J.; Wark, J. D.; Weisinger, H. S.; Jois, M.; Weisinger, R. S. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc. Natl. Acad. Sci. U S A, 2008, 105, 6531-6536 (Pubitemid 351754541)
132. Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Kaji, K.; Aihara, Y.; Yamazaki, M.; Yamao, J.; Toyohara, M.; Mitoro, A.; Sawai, M.; Yoshida, M.; Morioka, C.; Fujimoto, M.; Uemura, M.; Fukui, H. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial. Oncol. Rep., 2011, 26, 1547-1553
133. Storz, P. Reactive oxygen species in tumor progression. Front. Biosci., 2005, 10, 1881-1896 (Pubitemid 40529044)
134. Novitskiy, G.; Potter, J. J.; Wang, L.; Mezey, E. Influences of reactive oxygen species and nitric oxide on hepatic fibrogenesis. Liver Int., 2006, 26, 1248-1257 (Pubitemid 44741213)
135. Sasaki, Y. Does oxidative stress participate in the development of hepatocellular carcinoma? J. Gastroenterol., 2006, 41, 1135-1148 (Pubitemid 46487204)
136. Parola, M.; Robino, G. Oxidative stress-related molecules and liver fibrosis. J. Hepatol., 2001, 35, 297-306 (Pubitemid 32803489)
137. Greenwel, P.; Dominguez-Rosales, J. A.; Mavi, G.; Rivas-Estilla, A. M.; Rojkind, M. Hydrogen peroxide: a link between acetaldehyde-elicited alpha1 (I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology, 2000, 31, 109-116 (Pubitemid 30033696)
138. Kim, K. Y.; Choi, I.; Kim, S. S. Progression of hepatic stellate cell activation is associated with the level of oxidative stress rather than cytokines during CCl4-induced fibrogenesis. Mol. Cells, 2000, 10, 289-300
139. Mato, J. M.; Camara, J.; Fernandez de Paz, J.; Caballeria, L.; Coll, S.; Caballero, A.; Garcia-Buey, L.; Beltran, J.; Benita, V.; Caballeria, J.; Sola, R.; Moreno-Otero, R.; Barrao, F.; Martin-Duce, A.; Correa, J. A.; Pares, A.; Barrao, E.; Garcia-Magaz, I.; Puerta, J. L.; Moreno, J.; Boissard, G.; Ortiz, P.; Rodes, J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol., 1999, 30, 1081-1089 (Pubitemid 29278753)
140. Zhong, Z.; Froh, M.; Wheeler, M. D.; Smutney, O.; Lehmann, T. G.; Thurman, R. G. Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther., 2002, 9, 183-191 (Pubitemid 34189578)
141. Nieto, N.; Friedman, S. L.; Cederbaum, A. I. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology, 2002, 35, 62-73 (Pubitemid 34032544)
142. Adachi, T.; Togashi, H.; Suzuki, A.; Kasai, S.; Ito, J.; Sugahara, K.; Kawata, S., NAD (P) H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology, 2005, 41, 1272-1281 (Pubitemid 40770279)
143. De Minicis, S.; Brenner, D. A. NOX in liver fibrosis. Arch. Biochem. Biophys., 2007, 462, 266-272 (Pubitemid 46856330)
144. Bataller, R.; Schwabe, R. F.; Choi, Y. H.; Yang, L.; Paik, Y. H.; Lindquist, J.; Qian, T.; Schoonhoven, R.; Hagedorn, C. H.; Lemasters, J. J.; Brenner, D. A. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest., 2003, 112, 1383-1394 (Pubitemid 38057692)
145. Chen, Q.; Ames, B. N. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc. Natl. Acad. Sci. U S A, 1994, 91, 4130-4134 (Pubitemid 24143386)
146. Nishikawa, T.; Nakajima, T.; Katagishi, T.; Okada, Y.; Jo, M.; Kagawa, K.; Okanoue, T.; Itoh, Y.; Yoshikawa, T. Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int., 2009, 29, 846-856
147. Jo, M.; Nishikawa, T.; Nakajima, T.; Okada, Y.; Yamaguchi, K.; Mitsuyoshi, H.; Yasui, K.; Minami, M.; Iwai, M.; Kagawa, K.; Itoh, Y.; Yoshikawa, T. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J. Gastroenterol., 46, 809-821
148. Fujita, N.; Sugimoto, R.; Takeo, M.; Urawa, N.; Mifuji, R.; Tanaka, H.; Kobayashi, Y.; Iwasa, M.; Watanabe, S.; Adachi, Y.; Kaito, M. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol. Med., 2007, 13, 97-104 (Pubitemid 46786838)
149. Nishina, S.; Hino, K.; Korenaga, M.; Vecchi, C.; Pietrangelo, A.; Mizukami, Y.; Furutani, T.; Sakai, A.; Okuda, M.; Hidaka, I.; Okita, K.; Sakaida, I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology, 2008, 134, 226-238 (Pubitemid 350309316)
150. Kaito, M.; Iwasa, M.; Kobayashi, Y.; Fujita, N.; Tanaka, H.; Gabazza, E. C.; Adachi, Y.; Kojima, Y.; Nakagawa, N.; Watanabe, S. Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C. J. Gastroenterol., 2006, 41, 921-922 (Pubitemid 44594236)
151. Kato, J.; Miyanishi, K.; Kobune, M.; Nakamura, T.; Takada, K.; Takimoto, R.; Kawano, Y.; Takahashi, S.; Takahashi, M.; Sato, Y.; Takayama, T.; Niitsu, Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol., 2007, 42, 830-836 (Pubitemid 47617461)
152. Reid, A. E. Nonalcoholic steatohepatitis. Gastroenterology, 2001, 121, 710-723 (Pubitemid 32822586)
153. Fargion, S.; Mattioli, M.; Fracanzani, A. L.; Sampietro, M.; Tavazzi, D.; Fociani, P.; Taioli, E.; Valenti, L.; Fiorelli, G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 2448-2455 (Pubitemid 32769210)
154. George, D. K.; Goldwurm, S.; MacDonald, G. A.; Cowley, L. L.; Walker, N. I.; Ward, P. J.; Jazwinska, E. C.; Powell, L. W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114, 311-318 (Pubitemid 28093538)
155. Videla, L. A.; Fernandez, V.; Tapia, G.; Varela, P. Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals, 2003, 16, 103-111 (Pubitemid 36140221)
156. Tanaka, H.; Fujita, N.; Sugimoto, R.; Urawa, N.; Horiike, S.; Kobayashi, Y.; Iwasa, M.; Ma, N.; Kawanishi, S.; Watanabe, S.; Kaito, M.; Takei, Y. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br. J. Cancer, 2008, 98, 580-586 (Pubitemid 351214532)
157. Sorrentino, P.; D'Angelo, S.; Ferbo, U.; Micheli, P.; Bracigliano, A.; Vecchione, R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J. Hepatol., 2009, 50, 351-357
158. Valenti, L.; Fracanzani, A. L.; Dongiovanni, P.; Bugianesi, E.; Marchesini, G.; Manzini, P.; Vanni, E.; Fargion, S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am. J. Gastroenterol., 2007, 102, 1251-1258 (Pubitemid 46802029)
159. Yamamoto, M.; Iwasa, M.; Iwata, K.; Kaito, M.; Sugimoto, R.; Urawa, N.; Mifuji, R.; Konishi, M.; Kobayashi, Y.; Adachi, Y., Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol., 2007, 22, 498-503 (Pubitemid 46434977)
160. Sakaida, I.; Hironaka, K.; Uchida, K.; Okita, K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig. Dis. Sci., 1999, 44, 560-569 (Pubitemid 29137968)
161. Yamasaki, T.; Terai, S.; Sakaida, I. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J. Med., 2011, 365, 576-578
162. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Shirai, Y.; Aihara, Y.; Namisaki, T.; Yoshii, J.; Yanase, K.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2011, 300, G1094-1104
163. Ishizaka, N.; Saito, K.; Noiri, E.; Sata, M.; Ikeda, H.; Ohno, A.; Ando, J.; Mori, I.; Ohno, M.; Nagai, R. Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288, R1063-1070 (Pubitemid 40404184)
164. Woo, K. J.; Lee, T. J.; Park, J. W.; Kwon, T. K. Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. Biochem. Biophys. Res. Commun., 2006, 343, 8-14
165. Chong, T. W.; Horwitz, L. D.; Moore, J. W.; Sowter, H. M.; Harris, A. L. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Cancer Res., 2002, 62, 6924-6927 (Pubitemid 35424082)
166. Villanueva, A.; Chiang, D. Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguez, B.; Sole, M.; Battiston, C.; Van Laarhoven, S.; Fiel, M. I.; Di Feo, A.; Hoshida, Y.; Yea, S.; Toffanin, S.; Ramos, A.; Martignetti, J. A.; Mazzaferro, V.; Bruix, J.; Waxman, S.; Schwartz, M.; Meyerson, M.; Friedman, S. L.; Llovet, J. M. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology, 2008, 135, 1972-1983, 1983 e1-11
167. Fabris, C.; Smirne, C.; Fangazio, S.; Toniutto, P.; Burlone, M.; Minisini, R.; Bitetto, D.; Falleti, E.; Cerutti, A.; Pirisi, M. Influence of angiotensinconverting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatol. Res., 2009, 39, 795-804
168. Medeiros, R.; Vasconcelos, A.; Costa, S.; Pinto, D.; Lobo, F.; Morais, A.; Oliveira, J.; Lopes, C. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J. Pathol., 2004, 202, 330-335 (Pubitemid 38325242)
169. Yoneda, M.; Hotta, K.; Nozaki, Y.; Endo, H.; Uchiyama, T.; Mawatari, H.; Iida, H.; Kato, S.; Fujita, K.; Takahashi, H.; Kirikoshi, H.; Kobayashi, N.; Inamori, M.; Abe, Y.; Kubota, K.; Saito, S.; Maeyama, S.; Wada, K.; Nakajima, A. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int., 2009, 29, 1078-1085